Health Affairs August 26, 2024
In June, Gilead Sciences announced impressive early results from its PURPOSE 1 trial, which showed 100 percent efficacy of lenacapavir in preventing new HIV infections among cisgender women in Sub-Saharan Africa. Lenacapavir is being investigated as an injectable antiretroviral medication that can be taken once every six months as preexposure prophylaxis (PrEP) to prevent HIV. This is a marked shift from current PrEP options, which are only available as a once-daily pill or a bimonthly injection.
Once again, the HIV community finds itself at a scientific breakthrough moment. And once again, it remains an open question as to whether it will also prove to be a breakthrough moment for equitable access.
We have been down this road before. It was...
Today's Sponsors
Today's Sponsor